Clinical trial

Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics

NCT00458211

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2005-05-01

PhasePHASE4

Study timeline

Study start (unknown)2005-05-01Date precision: month

Registry last updated2020-05-01

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Schizophreniaunresolved

Schizoaffective Disorderunresolved

Interventions

ziprasidoneDRUG · verified · RxNorm: ziprasidone

Sponsors & collaborators

Bronx Psychiatric Centerlead sponsor

Pfizercollaborator

Buffalo Psychiatric Centercollaborator

Rochester Psychiatric Centercollaborator

Mapped research locations

The BronxNew York, United States1 BuffaloNew York, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00458211 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.